A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Inclusion Criteria: * Male or female patients ≥18 years of age. * Patients with advanced gastrointestinal stromal tumors. * Subjects who have progressed or documented intolerance after previous treatments. * Sign informed consent, understand the Protocol and could follow the Protocol. * The subject had at least one measurable lesion. * Adequate organ function and bone marrow reserve Exclusion Criteria: * Treatment with anticancer therapy, including investigational therapy, or investigational procedures within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of investigational drug. * Prior treatment with DCC-2618. * Previously or currently has an additional malignancy that is progressing or required active treatment, which may interfere with the safety or efficacy evaluation of DCC-2618. * Patient has known active central nervous system metastases. * New York Heart Association class II - IV heart disease, active ischemia or any other uncontrolled cardiac condition. * Arterial thrombotic or embolic events within 6 months before the first dose of investigational drug. * Venous thrombotic events within 3 months before the first dose of investigational drug. * 12-lead electrocardiogram (ECG) demonstrating QT interval corrected by Fridericia's formula \>450 ms in males or \>470 ms in females at screening or history of long QT interval syndrome. * Left ventricular ejection fraction (LVEF) \<50% at screening. * Use of known substrates or inhibitors of br…